NASDAQ:CASC Investor Alert: Investigation of Takeover of Cascadian Therapeutics Inc
The takeover of Cascadian Therapeutics Inc is under investigation over possible wrongdoing. The investigation was announced for investors, who currently hold NASDAQ:CASC shares, concerning whether the takeover of Cascadian Therapeutics Inc by Seattle Genetics, Inc for $10.00 per share is unfair.
View full press release